The Worst Case Scenario for a Therapeutic Device Deal

The worst thing that could happen would be a regulatory blockage of the deal. We think that this is very, very likely to be completed. And it's probably trading at like 75% implied in the market based upon where the stock is trading right now. So we think it's underpriced. It's inefficiently priced. If it's completed, you can successfully make a nice annualized rate of return.